Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mellicell Inc. is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This application is being examined by 1 distinct examiner in 1 distinct art unit. The current prosecution profile is focused on the active matter, which suggests a highly specialized technical focus for the company's current patent efforts. This concentration simplifies the management of the pending application.
The busiest examiner for this portfolio is JOHNSON, KARA D, who has 1 pending office action. With only 1 distinct examiner and 1 distinct art unit involved, the prosecution experience is currently centralized. Practitioners can tailor their strategy to the specific examination patterns of this individual within the Biotechnology & Pharmaceuticals field. A thorough review of the examiner's previous actions may provide valuable insights for navigating the current prosecution successfully.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, KARA D | 1 | 69.3% | +25.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286077 | CELL SYSTEM AND METHODS OF USE | JOHNSON, KARA D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286077 | CELL SYSTEM AND METHODS OF USE | JOHNSON, KARA D | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18286077 | CELL SYSTEM AND METHODS OF USE | JOHNSON, KARA D | 1632 | §102§103§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMellicell Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kara D Johnson has the most, with 1 of Mellicell Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
